ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
ENDRA Life Sciences Inc. (NDRA)
US:NASDAQ Investor Relations:
investors.endrainc.com/prviewer/release_only/id/2807436
Company Research
Source: Business Wire
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”).On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq’s maintenance requirements for listing.“Now that we have regained compliance with Nasdaq’s listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,” said Alex Tokman, acting Chief Executive Officer of ENDRA.About ENDRA Life Sciences Inc.ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue
Show less
Read more
Impact Snapshot
Event Time:
NDRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NDRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NDRA alerts
High impacting ENDRA Life Sciences Inc. news events
Weekly update
A roundup of the hottest topics
NDRA
News
- ENDRA Life Sciences (NASDAQ:NDRA) had its price target lowered by analysts at Ascendiant Capital Markets from $38.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial UseBusiness Wire
- ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH BiomarkerBusiness Wire
- ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial ResultsBusiness Wire
- ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCABusiness Wire
NDRA
Analyst Actions
- 12/8/25 - Ascendiant Capital
NDRA
Sec Filings
- 12/15/25 - Form 8-K
- 11/28/25 - Form 8-K
- 11/26/25 - Form SCHEDULE
- NDRA's page on the SEC website